These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21666343)

  • 21. Drugs, diagnostic tests approved quickly.
    Rose S
    Cancer Discov; 2011 Oct; 1(5):371. PubMed ID: 22586620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective.
    Wong EH; Yocca F; Smith MA; Lee CM
    Int J Neuropsychopharmacol; 2010 Oct; 13(9):1269-84. PubMed ID: 20716397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Translational research: The American way.
    Maxmen A
    Nature; 2011 Oct; 478(7368):S16-8. PubMed ID: 21993821
    [No Abstract]   [Full Text] [Related]  

  • 24. Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development.
    Stahel R; Bogaerts J; Ciardiello F; de Ruysscher D; Dubsky P; Ducreux M; Finn S; Laurent-Puig P; Peters S; Piccart M; Smit E; Sotiriou C; Tejpar S; Van Cutsem E; Tabernero J
    Cancer Treat Rev; 2015 Feb; 41(2):129-35. PubMed ID: 25533737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapeutic strategies for neoplasia.
    Talmadge JE
    Dev Biol Stand; 1992; 77():17-28. PubMed ID: 1426659
    [No Abstract]   [Full Text] [Related]  

  • 26. Drug discovery: playing dirty.
    Frantz S
    Nature; 2005 Oct; 437(7061):942-3. PubMed ID: 16222266
    [No Abstract]   [Full Text] [Related]  

  • 27. Immunotoxin therapy of malignancy.
    Grossbard ML; Nadler LM
    Important Adv Oncol; 1992; ():111-35. PubMed ID: 1582669
    [No Abstract]   [Full Text] [Related]  

  • 28. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
    Dalmases A; Rojo F; Rovira A; Albanell J
    Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
    [No Abstract]   [Full Text] [Related]  

  • 29. [Immune Checkpoint for a Kidney Cancer and Other Cancers].
    Kageyama S; Yamaguchi S; Miura K; Kato S
    Gan To Kagaku Ryoho; 2016 Jun; 43(6):672-7. PubMed ID: 27306804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Approving molecularly targeted drugs: different approval processes for cytotoxic agents.
    Sasahara Y; Narimatsu H; Fukao A; Yoshioka T
    Int J Clin Oncol; 2016 Oct; 21(5):1004-1013. PubMed ID: 27105626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioethics and post-approval research in translational science.
    Chen JY; Carter M
    Am J Bioeth; 2010 Aug; 10(8):35-7. PubMed ID: 20694904
    [No Abstract]   [Full Text] [Related]  

  • 32. Combinations of targeted therapies in human cancers.
    Decaudin D; Le Tourneau C
    Aging (Albany NY); 2016 Oct; 8(10):2258-2259. PubMed ID: 27783563
    [No Abstract]   [Full Text] [Related]  

  • 33. Translational research may be most successful when it fails.
    Ioannidis JP
    Hastings Cent Rep; 2015; 45(2):39-40. PubMed ID: 25739779
    [No Abstract]   [Full Text] [Related]  

  • 34. [Cancer translational research in Japan].
    Wada S; Nishiyama M
    Nihon Yakurigaku Zasshi; 2010 Nov; 136(5):294-7. PubMed ID: 21079370
    [No Abstract]   [Full Text] [Related]  

  • 35. The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective.
    Perry WL; Weitzman A
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):199-202, 237-8. PubMed ID: 16166991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.
    Lee HW; Lee JI; Lee SJ; Cho HJ; Song HJ; Jeong DE; Seo YJ; Shin S; Joung JG; Kwon YJ; Choi YL; Park WY; Lee HM; Seol HJ; Shim YM; Joo KM; Nam DH
    Clin Cancer Res; 2015 Mar; 21(5):1172-82. PubMed ID: 25549722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges ahead for companion diagnostics.
    Schmidt C
    J Natl Cancer Inst; 2012 Jan; 104(1):14-5. PubMed ID: 22173588
    [No Abstract]   [Full Text] [Related]  

  • 38. Personalized-medicine trials on the rise.
    Benowitz S
    J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496
    [No Abstract]   [Full Text] [Related]  

  • 39. Make better, safer biomaterials.
    Peppas NA; Khademhosseini A
    Nature; 2016 Dec; 540(7633):335-337. PubMed ID: 27974790
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug discovery strategies in the field of tumor energy metabolism: Limitations by metabolic flexibility and metabolic resistance to chemotherapy.
    Amoedo ND; Obre E; Rossignol R
    Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):674-685. PubMed ID: 28213330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.